Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06585553
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Atrophic Gastritis and OLGIM Stage
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Patients with Intestinal Metaplasia in the Lesser Curvature of the Gastric Corpus Require OLGIM Staging a Secondary Analysis of a Prospective Cohort
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Three clinical research coordinators recruited patients aged 40-75 who underwent screening endoscopy at the Digestive Endoscopy Center of Qilu Hospital from July 1 2022 to July 30 2024 All participating patients provided written informed consent Baseline information such as height weight age sex smoking and alcohol consumption status HP status and family history of gastrointestinal tumors were recorded before endoscopy During endoscopy the endoscopist observed and photographed the lesser and greater curvature of the antrum corpus and incisura performed the Kimura-Takemoto classification and classified those with a Kimura-Takemoto score of C0 as non-atrophic gastritis and those with C1-O3 as atrophic gastritis Patients with atrophic gastritis received free multiple-site biopsies for pathological assessment including targeted biopsies of suspected IM areas and random biopsies from Sydney classification sites At least four biopsies were taken from the lesser and greater curvature of the antrum and corpus for pathological evaluation and OLGIM staging was calculated based on the results
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None